ArticleFrontiers in immunology2018
High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer.
Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 144 citations in OpenAlex.
- Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies ProducedFrontiers in immunology · 2018Trial
- Dense Plasma Cell Infiltrates Foster Stromal Desmoplasia and Immune Evasion in Oral Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2026Article
- Diagnostic plasma protein signatures in sporadic and BRCA1/2 breast cancer patients via targeted proteomics.Breast cancer research : BCR · 2026Article
- Analytical validity of CD20 as a biomarker in breast cancer patients using tissue microarrays and whole slide sections.Biomarkers in medicine · 2026Article
- Multimodal single-cell and spatial profiling reveals altered T cell-mediated immunity and B-cell follicular architecture in non-metastatic lymph nodes of patients with aggressive non-small cell lung cancer.medRxiv : the preprint server for health sciences · 2026Article
- Exploring the prognostic value and biomarker of TEX11 in breast cancer via PANoptosis.Breast cancer (Tokyo, Japan) · 2026Article
- Guardians of immunity: the role of tumour-draining lymph node in cancer immunity.Frontiers in cell and developmental biology · 2026Review
- Case Report: Post-mortem analysis of long-term inflammation after mild COVID-19.Frontiers in immunology · 2026Article
- Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses.Science translational medicine · 2025Article
- Enhanced prediction of breast cancer patient response to chemotherapy by integrating deconvolved expression patterns of immune, stromal and tumor cells.bioRxiv : the preprint server for biology · 2025Article
- stClinic dissects clinically relevant niches by integrating spatial multi-slice multi-omics data in dynamic graphs.Nature communications · 2025Article
- Article
- Spatially Resolved Tumor Ecosystems and Cell States in Gastric Adenocarcinoma Progression and Evolution.Cancer discovery · 2025Article
- Article
- Multifaceted function of B cells in tumorigenesis.Frontiers of medicine · 2025Review
- Immune Microenvironment in Breast Cancer Metastasis.Advances in experimental medicine and biology · 2025Review
- Immunogenic Cell Death Genes Related Prognostic Biomarker in Hepatocellular Carcinoma.Oncology research · 2025Article
- Increased PRP19 in Hepatocyte Impedes B Cell Function to Promote Hepatocarcinogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common malignancy affecting women, but the heterogeneity of the condition is a significant obstacle to effective treatment. Triple negative breast cancers (TNBCs) do not express HER2 or the receptors for estrogen or progesterone, and so often have a poor prognosis. Tumor-infiltrating T cells have been well-characterized in TNBC, and increased numbers are associated with better outcomes; however, the potential roles of B cells and plasma cells have been large. Here, we conducted a retrospective correlative study on the expression of B cell/plasma cell-related genes, and the abundance and localization of B cells and plasma cells within TNBCs, and clinical outcome. We analyzed 269 TNBC samples and used immunohistochemistry to quantify tumor-infiltrating B cells and plasma cells, coupled with NanoString measurement of expression of immunoglobulin metagenes. Multivariate analysis revealed that patients bearing TNBCs with above-median densities of CD38
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.